{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T15:52:09Z","timestamp":1790092329448,"version":"4.0.1"},"reference-count":197,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T00:00:00Z","timestamp":1749427200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82160043"],"award-info":[{"award-number":["82160043"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Innovation Base Construction Project of Jiangxi Province","award":["20212BCG74001"],"award-info":[{"award-number":["20212BCG74001"]}]},{"name":"Jiangxi Provincial Key Laboratory of Hematological Diseases","award":["2024SSY06051"],"award-info":[{"award-number":["2024SSY06051"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clinic Rev Allerg Immunol"],"DOI":"10.1007\/s12016-025-09068-9","type":"journal-article","created":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:04:43Z","timestamp":1749416683000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Promising Targeted Therapies for Hemophagocytic Lymphohistiocytosis: A Translational Perspective Based on Immunopathology"],"prefix":"10.1007","volume":"68","author":[{"given":"Yuanyuan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songtao","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialiang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaowu","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,9]]},"reference":[{"key":"9068_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/tcrm.S195538","volume":"17","author":"H Yildiz","year":"2021","unstructured":"Yildiz H, Bailly S, Van Den Neste E, Yombi JC (2021) Clinical management of relapsed\/refractory hemophagocytic lymphohistiocytosis in adult patients: a review of current strategies and emerging therapies. Ther Clin Risk Manag 17:293\u2013304. https:\/\/doi.org\/10.2147\/tcrm.S195538","journal-title":"Ther Clin Risk Manag"},{"issue":"25","key":"9068_CR2","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten E, Horne A, Aric\u00f3 M, Astigarraga I, Egeler RM, Filipovich AH et al (2017) Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood 130(25):2728\u20132738. https:\/\/doi.org\/10.1182\/blood-2017-06-788349","journal-title":"Blood"},{"issue":"23","key":"9068_CR3","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Ros\u00e9e","year":"2019","unstructured":"La Ros\u00e9e P, Horne A, Hines M, von Bahr GT, Machowicz R, Berliner N et al (2019) Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood 133(23):2465\u20132477. https:\/\/doi.org\/10.1182\/blood.2018894618","journal-title":"Blood"},{"issue":"3","key":"9068_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/s12276-024-01182-6","volume":"56","author":"TTT Nguyen","year":"2024","unstructured":"Nguyen TTT, Kim YT, Jeong G, Jin M (2024) Immunopathology of and potential therapeutics for secondary hemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a translational perspective. Exp Mol Med 56(3):559\u2013569. https:\/\/doi.org\/10.1038\/s12276-024-01182-6","journal-title":"Exp Mol Med"},{"issue":"12","key":"9068_CR5","doi-asserted-by":"publisher","first-page":"e12049","DOI":"10.7759\/cureus.12049","volume":"12","author":"HH Khan","year":"2020","unstructured":"Khan HH, Ansar I, Kontos N, Kumar S, Lyons H (2020) Report of a fatal case of hemophagocytic lymphohistiocytosis syndrome and a review of the literature. Cureus 12(12):e12049. https:\/\/doi.org\/10.7759\/cureus.12049","journal-title":"Cureus"},{"issue":"10","key":"9068_CR6","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1111\/apa.15900","volume":"110","author":"U Andersson","year":"2021","unstructured":"Andersson U (2021) Hyperinflammation: on the pathogenesis and treatment of macrophage activation syndrome. Acta Paediatr 110(10):2717\u20132722. https:\/\/doi.org\/10.1111\/apa.15900","journal-title":"Acta Paediatr"},{"key":"9068_CR7","doi-asserted-by":"publisher","first-page":"608492","DOI":"10.3389\/fimmu.2020.608492","volume":"11","author":"P Merli","year":"2020","unstructured":"Merli P, Algeri M, Gaspari S, Locatelli F (2020) Novel therapeutic approaches to familial HLH (emapalumab in FHL). Front Immunol 11:608492. https:\/\/doi.org\/10.3389\/fimmu.2020.608492","journal-title":"Front Immunol"},{"issue":"8","key":"9068_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nri2803","volume":"10","author":"BG de Saint","year":"2010","unstructured":"de Saint BG, M\u00e9nasch\u00e9 G, Fischer A (2010) Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol 10(8):568\u2013579. https:\/\/doi.org\/10.1038\/nri2803","journal-title":"Nat Rev Immunol"},{"key":"9068_CR9","doi-asserted-by":"crossref","unstructured":"Stepp SE, Dufourcq-Lagelouse R, Kumar V. Pillars article: perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999. 286: 1957\u20131959. J Immunol. 2015;194(11):5044\u20135046.","DOI":"10.1093\/jimmunol\/194.11.5044"},{"issue":"5","key":"9068_CR10","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1002\/(sici)1096-911x(199805)30:5<276::aid-mpo3>3.0.co;2-c","volume":"30","author":"E Ishii","year":"1998","unstructured":"Ishii E, Ohga S, Tanimura M, Imashuku S, Sako M, Mizutani S et al (1998) Clinical and epidemiologic studies of familial hemophagocytic lymphohistiocytosis in Japan. Japan LCH Study Group. Med Pediatr Oncol 30(5):276\u2013283. https:\/\/doi.org\/10.1002\/(sici)1096-911x(199805)30:5%3c276::aid-mpo3%3e3.0.co;2-c","journal-title":"Med Pediatr Oncol"},{"issue":"7","key":"9068_CR11","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3324\/haematol.11233","volume":"92","author":"K Nagafuji","year":"2007","unstructured":"Nagafuji K, Nonami A, Kumano T, Kikushige Y, Yoshimoto G, Takenaka K et al (2007) Perforin gene mutations in adult-onset hemophagocytic lymphohistiocytosis. Haematologica 92(7):978\u2013981. https:\/\/doi.org\/10.3324\/haematol.11233","journal-title":"Haematologica"},{"issue":"1","key":"9068_CR12","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1002\/pbc.22499","volume":"55","author":"RA Marsh","year":"2010","unstructured":"Marsh RA, Satake N, Biroschak J, Jacobs T, Johnson J, Jordan MB et al (2010) STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer 55(1):134\u2013140. https:\/\/doi.org\/10.1002\/pbc.22499","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"9068_CR13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1007\/s10875-017-0443-1","volume":"37","author":"S Ammann","year":"2017","unstructured":"Ammann S, Lehmberg K, Zur Stadt U, Klemann C, Bode SFN, Speckmann C et al (2017) Effective immunological guidance of genetic analyses including exome sequencing in patients evaluated for hemophagocytic lymphohistiocytosis. J Clin Immunol 37(8):770\u2013780. https:\/\/doi.org\/10.1007\/s10875-017-0443-1","journal-title":"J Clin Immunol"},{"issue":"2","key":"9068_CR14","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/bjh.14147","volume":"174","author":"E Brisse","year":"2016","unstructured":"Brisse E, Wouters CH, Matthys P (2016) Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities. Br J Haematol 174(2):203\u2013217. https:\/\/doi.org\/10.1111\/bjh.14147","journal-title":"Br J Haematol"},{"issue":"5680","key":"9068_CR15","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1126\/science.1095291","volume":"305","author":"J Stinchcombe","year":"2004","unstructured":"Stinchcombe J, Bossi G, Griffiths GM (2004) Linking albinism and immunity: the secrets of secretory lysosomes. Science 305(5680):55\u201359. https:\/\/doi.org\/10.1126\/science.1095291","journal-title":"Science"},{"issue":"1","key":"9068_CR16","doi-asserted-by":"publisher","first-page":"R30","DOI":"10.1186\/ar1453","volume":"7","author":"J Villanueva","year":"2005","unstructured":"Villanueva J, Lee S, Giannini EH, Graham TB, Passo MH, Filipovich A et al (2005) Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 7(1):R30-37. https:\/\/doi.org\/10.1186\/ar1453","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"9068_CR17","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1016\/S0022-2275(20)38349-8","volume":"30","author":"C Grunfeld","year":"1989","unstructured":"Grunfeld C, Gulli R, Moser AH, Gavin LA, Feingold KR (1989) Effect of tumor necrosis factor administration in vivo on lipoprotein lipase activity in various tissues of the rat. J Lipid Res 30(4):579\u2013585","journal-title":"J Lipid Res"},{"issue":"25","key":"9068_CR18","doi-asserted-by":"publisher","first-page":"3699","DOI":"10.1182\/blood-2014-01-549527","volume":"124","author":"FC Lin","year":"2014","unstructured":"Lin FC, Karwan M, Saleh B, Hodge DL, Chan T, Boelte KC et al (2014) IFN-\u03b3 causes aplastic anemia by altering hematopoietic stem\/progenitor cell composition and disrupting lineage differentiation. Blood 124(25):3699\u20133708. https:\/\/doi.org\/10.1182\/blood-2014-01-549527","journal-title":"Blood"},{"issue":"9","key":"9068_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/ped.13064","volume":"58","author":"A Morimoto","year":"2016","unstructured":"Morimoto A, Nakazawa Y, Ishii E (2016) Hemophagocytic lymphohistiocytosis: pathogenesis, diagnosis, and management. Pediatr Int 58(9):817\u2013825. https:\/\/doi.org\/10.1111\/ped.13064","journal-title":"Pediatr Int"},{"issue":"17","key":"9068_CR20","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1182\/blood.2020009499","volume":"137","author":"V Chaturvedi","year":"2021","unstructured":"Chaturvedi V, Marsh RA, Zoref-Lorenz A, Owsley E, Chaturvedi V, Nguyen TC et al (2021) T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis. Blood 137(17):2337\u20132346. https:\/\/doi.org\/10.1182\/blood.2020009499","journal-title":"Blood"},{"issue":"8","key":"9068_CR21","doi-asserted-by":"publisher","first-page":"e29686","DOI":"10.1016\/j.heliyon.2024.e29686","volume":"10","author":"SP Dash","year":"2024","unstructured":"Dash SP, Gupta S, Sarangi PP (2024) Monocytes and macrophages: origin, homing, differentiation, and functionality during inflammation. Heliyon 10(8):e29686. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e29686","journal-title":"Heliyon"},{"issue":"1","key":"9068_CR22","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1111\/imr.12336","volume":"268","author":"A Getahun","year":"2015","unstructured":"Getahun A, Cambier JC (2015) Of ITIMs, ITAMs, and ITAMis: revisiting immunoglobulin Fc receptor signaling. Immunol Rev 268(1):66\u201373. https:\/\/doi.org\/10.1111\/imr.12336","journal-title":"Immunol Rev"},{"issue":"9","key":"9068_CR23","doi-asserted-by":"publisher","first-page":"3867","DOI":"10.1182\/blood-2007-11-126029","volume":"112","author":"W Tian","year":"2008","unstructured":"Tian W, Li XJ, Stull ND, Ming W, Suh CI, Bissonnette SA et al (2008) Fc gamma R-stimulated activation of the NADPH oxidase: phosphoinositide-binding protein p40phox regulates NADPH oxidase activity after enzyme assembly on the phagosome. Blood 112(9):3867\u20133877. https:\/\/doi.org\/10.1182\/blood-2007-11-126029","journal-title":"Blood"},{"key":"9068_CR24","doi-asserted-by":"publisher","first-page":"21","DOI":"10.12688\/f1000research.12679.1","volume":"7","author":"M Lennartz","year":"2018","unstructured":"Lennartz M, Drake J (2018) Molecular mechanisms of macrophage Toll-like receptor-Fc receptor synergy. F1000Res 7:21. https:\/\/doi.org\/10.12688\/f1000research.12679.1","journal-title":"F1000Res"},{"issue":"1","key":"9068_CR25","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1111\/imr.12333","volume":"268","author":"M van Egmond","year":"2015","unstructured":"van Egmond M, Vidarsson G, Bakema JE (2015) Cross-talk between pathogen recognizing Toll-like receptors and immunoglobulin Fc receptors in immunity. Immunol Rev 268(1):311\u2013327. https:\/\/doi.org\/10.1111\/imr.12333","journal-title":"Immunol Rev"},{"issue":"10","key":"9068_CR26","doi-asserted-by":"publisher","first-page":"2729","DOI":"10.1111\/apa.15973","volume":"110","author":"S Imashuku","year":"2021","unstructured":"Imashuku S, Morimoto A, Ishii E (2021) Virus-triggered secondary hemophagocytic lymphohistiocytosis. Acta Paediatr 110(10):2729\u20132736. https:\/\/doi.org\/10.1111\/apa.15973","journal-title":"Acta Paediatr"},{"issue":"1","key":"9068_CR27","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1186\/s12879-021-06408-w","volume":"21","author":"H Mottaghipisheh","year":"2021","unstructured":"Mottaghipisheh H, Kalantar K, Amanati A, Shokripour M, Shahriari M, Zekavat OR et al (2021) Comparison of the clinical features and outcome of children with hemophagocytic lymphohistiocytosis (HLH) secondary to visceral leishmaniasis and primary HLH: a single-center study. BMC Infect Dis 21(1):732. https:\/\/doi.org\/10.1186\/s12879-021-06408-w","journal-title":"BMC Infect Dis"},{"issue":"6","key":"9068_CR28","doi-asserted-by":"publisher","first-page":"507","DOI":"10.3760\/cma.j.issn.0253-2727.2015.06.013","volume":"36","author":"X Zeng","year":"2015","unstructured":"Zeng X, Wei N, Wang Y, Wang J, Zhang J, Wu L et al (2015) Treatment outcomes and prognostic analysis of 61 Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis. Zhonghua Xue Ye Xue Za Zhi 36(6):507\u2013510. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2015.06.013","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"9068_CR29","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3389\/fonc.2019.00713","volume":"9","author":"C Shannon-Lowe","year":"2019","unstructured":"Shannon-Lowe C, Rickinson A (2019) The global landscape of EBV-associated tumors. Front Oncol 9:713. https:\/\/doi.org\/10.3389\/fonc.2019.00713","journal-title":"Front Oncol"},{"issue":"1","key":"9068_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1182\/blood.2023021074","volume":"143","author":"J Wang","year":"2024","unstructured":"Wang J, Su M, Wei N, Yan H, Zhang J, Gong Y et al (2024) Chronic active Epstein-Barr virus disease originates from infected hematopoietic stem cells. Blood 143(1):32\u201341. https:\/\/doi.org\/10.1182\/blood.2023021074","journal-title":"Blood"},{"key":"9068_CR31","doi-asserted-by":"publisher","first-page":"107606","DOI":"10.1016\/j.intimp.2021.107606","volume":"96","author":"GQ Meng","year":"2021","unstructured":"Meng GQ, Wang JS, Wang YN, Wei N, Wang Z (2021) Rituximab-containing immuno-chemotherapy regimens are effective for the elimination of EBV for EBV-HLH with only and mainly B lymphocytes of EBV infection. Int Immunopharmacol 96:107606. https:\/\/doi.org\/10.1016\/j.intimp.2021.107606","journal-title":"Int Immunopharmacol"},{"issue":"3","key":"9068_CR32","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1111\/bjh.12386","volume":"162","author":"D Chellapandian","year":"2013","unstructured":"Chellapandian D, Das R, Zelley K, Wiener SJ, Zhao H, Teachey DT et al (2013) Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol 162(3):376\u2013382. https:\/\/doi.org\/10.1111\/bjh.12386","journal-title":"Br J Haematol"},{"issue":"5","key":"9068_CR33","doi-asserted-by":"publisher","first-page":"855","DOI":"10.3109\/14397595.2013.874740","volume":"24","author":"MW So","year":"2014","unstructured":"So MW, Koo BS, Kim YJ, Kim YG, Lee CK, Yoo B (2014) Successful rituximab treatment of refractory hemophagocytic lymphohistiocytosis and autoimmune hemolytic anemia associated with systemic lupus erythematosus. Mod Rheumatol 24(5):855\u2013857. https:\/\/doi.org\/10.3109\/14397595.2013.874740","journal-title":"Mod Rheumatol"},{"issue":"2","key":"9068_CR34","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1159\/000517023","volume":"14","author":"BE Nelson","year":"2021","unstructured":"Nelson BE, Hong A, Dekmezian M, Jana B (2021) Standard-dose rituximab as effective therapy for treating malignancy-related hemophagocytic lymphohistiocytosis in the eldery: a case report. Case Rep Oncol 14(2):1066\u20131070. https:\/\/doi.org\/10.1159\/000517023","journal-title":"Case Rep Oncol"},{"issue":"11","key":"9068_CR35","doi-asserted-by":"publisher","first-page":"6088","DOI":"10.1074\/jbc.270.11.6088","volume":"270","author":"A Treumann","year":"1995","unstructured":"Treumann A, Lifely MR, Schneider P, Ferguson MA (1995) Primary structure of CD52. J Biol Chem 270(11):6088\u20136099. https:\/\/doi.org\/10.1074\/jbc.270.11.6088","journal-title":"J Biol Chem"},{"key":"9068_CR36","doi-asserted-by":"publisher","unstructured":"Xia MQ, Hale G, Lifely MR, Ferguson MA, Campbell D, Packman L, et al (1993) Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis. Biochem J 293 ( Pt 3)(Pt 3):633\u2013640. https:\/\/doi.org\/10.1042\/bj2930633.","DOI":"10.1042\/bj2930633"},{"issue":"1","key":"9068_CR37","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1006\/jmbi.1998.2157","volume":"284","author":"GM Cheetham","year":"1998","unstructured":"Cheetham GM, Hale G, Waldmann H, Bloomer AC (1998) Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart. J Mol Biol 284(1):85\u201399. https:\/\/doi.org\/10.1006\/jmbi.1998.2157","journal-title":"J Mol Biol"},{"issue":"1","key":"9068_CR38","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/mrd.1080340103","volume":"34","author":"C Kirchhoff","year":"1993","unstructured":"Kirchhoff C, Krull N, Pera I, Ivell R (1993) A major mRNA of the human epididymal principal cells, HE5, encodes the leucocyte differentiation CDw52 antigen peptide backbone. Mol Reprod Dev 34(1):8\u201315. https:\/\/doi.org\/10.1002\/mrd.1080340103","journal-title":"Mol Reprod Dev"},{"issue":"9856","key":"9068_CR39","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/s0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP et al (2012) Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 380(9856):1819\u20131828. https:\/\/doi.org\/10.1016\/s0140-6736(12)61769-3","journal-title":"Lancet"},{"issue":"4","key":"9068_CR40","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40265-014-0195-7","volume":"74","author":"KP Garnock-Jones","year":"2014","unstructured":"Garnock-Jones KP (2014) Alemtuzumab: a review of its use in patients with relapsing multiple sclerosis. Drugs 74(4):489\u2013504. https:\/\/doi.org\/10.1007\/s40265-014-0195-7","journal-title":"Drugs"},{"key":"9068_CR41","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jns.2016.02.025","volume":"363","author":"EJ Fox","year":"2016","unstructured":"Fox EJ, Wynn D, Coles AJ, Palmer J, Margolin DH (2016) Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients. J Neurol Sci 363:188\u2013194. https:\/\/doi.org\/10.1016\/j.jns.2016.02.025","journal-title":"J Neurol Sci"},{"issue":"2","key":"9068_CR42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/tme.12292","volume":"26","author":"YM Hui","year":"2016","unstructured":"Hui YM, Regan F, Willecombe M, Taube D (2016) Use of non-irradiated blood components in Campath (alemtuzumab)-treated renal transplant patients. Transfus Med 26(2):138\u2013146. https:\/\/doi.org\/10.1111\/tme.12292","journal-title":"Transfus Med"},{"issue":"1","key":"9068_CR43","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s13045-024-01621-x","volume":"17","author":"Y Wu","year":"2024","unstructured":"Wu Y, Sun X, Kang K, Yang Y, Li H, Zhao A et al (2024) Hemophagocytic lymphohistiocytosis: current treatment advances, emerging targeted therapy and underlying mechanisms. J Hematol Oncol 17(1):106. https:\/\/doi.org\/10.1186\/s13045-024-01621-x","journal-title":"J Hematol Oncol"},{"key":"9068_CR44","doi-asserted-by":"crossref","unstructured":"Moshous D, Briand C, Castelle M, Dupic L, Morelle G, Chahla WA, et al (2019) Alemtuzumab as first line treatment in children with familial lymphohistiocytosis. Blood","DOI":"10.1182\/blood-2019-124477"},{"issue":"6","key":"9068_CR45","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1182\/blood-2012-06-432500","volume":"121","author":"RA Marsh","year":"2013","unstructured":"Marsh RA, Rao K, Satwani P, Lehmberg K, M\u00fcller I, Li D et al (2013) Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. Blood 121(6):877\u2013883. https:\/\/doi.org\/10.1182\/blood-2012-06-432500","journal-title":"Blood"},{"key":"9068_CR46","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1182\/blood-2019-124477","volume":"134","author":"D Moshous","year":"2019","unstructured":"Moshous D, Briand C, Castelle M, Dupic L, Morelle G, Abou Chahla W et al (2019) Alemtuzumab as first line treatment in children with familial lymphohistiocytosis. Blood 134:80. https:\/\/doi.org\/10.1182\/blood-2019-124477","journal-title":"Blood"},{"issue":"3","key":"9068_CR47","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1097\/RHU.0b013e31824e8d9b","volume":"18","author":"MP Keith","year":"2012","unstructured":"Keith MP, Pitchford C, Bernstein WB (2012) Treatment of hemophagocytic lymphohistiocytosis with alemtuzumab in systemic lupus erythematosus. J Clin Rheumatol 18(3):134\u2013137. https:\/\/doi.org\/10.1097\/RHU.0b013e31824e8d9b","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"9068_CR48","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1002\/pbc.24188","volume":"60","author":"RA Marsh","year":"2013","unstructured":"Marsh RA, Allen CE, McClain KL, Weinstein JL, Kanter J, Skiles J et al (2013) Salvage therapy of refractory hemophagocytic lymphohistiocytosis with alemtuzumab. Pediatr Blood Cancer 60(1):101\u2013109. https:\/\/doi.org\/10.1002\/pbc.24188","journal-title":"Pediatr Blood Cancer"},{"key":"9068_CR49","doi-asserted-by":"publisher","unstructured":"Bauer MP, van Burgel ND, Marijt WA, van Dissel JT, von dem Borne PA (2009) Fever, shock, and pancytopenia in a patient treated with alemtuzumab. Clin Infect Dis. 49(10):1540; 1616\u20131547. https:\/\/doi.org\/10.1086\/644730.","DOI":"10.1086\/644730"},{"key":"9068_CR50","doi-asserted-by":"publisher","unstructured":"Machaczka M, Vaktn\u00e4s J, Chiang SC, Bryceson YT (2010) Alemtuzumab treatment for hemophagocytic lymphohistiocytosis. Nat Rev Clin Oncol 7(10). https:\/\/doi.org\/10.1038\/nrclinonc.2010.40-c1.","DOI":"10.1038\/nrclinonc.2010.40-c1"},{"issue":"10","key":"9068_CR51","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1016\/j.bbmt.2014.06.003","volume":"20","author":"RA Marsh","year":"2014","unstructured":"Marsh RA, Bleesing JJ, Chandrakasan S, Jordan MB, Davies SM, Filipovich AH (2014) Reduced-intensity conditioning hematopoietic cell transplantation is an effective treatment for patients with SLAM-associated protein deficiency\/X-linked lymphoproliferative disease type 1. Biol Blood Marrow Transplant 20(10):1641\u20131645. https:\/\/doi.org\/10.1016\/j.bbmt.2014.06.003","journal-title":"Biol Blood Marrow Transplant"},{"issue":"11","key":"9068_CR52","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1182\/bloodadvances.2022007012","volume":"7","author":"M Gooptu","year":"2023","unstructured":"Gooptu M, Kim HT, Jacobsen E, Fisher DC, LaCasce A, Ho VT et al (2023) Favorable outcomes following allogeneic transplantation in adults with hemophagocytic lymphohistiocytosis. Blood Adv 7(11):2309\u20132316. https:\/\/doi.org\/10.1182\/bloodadvances.2022007012","journal-title":"Blood Adv"},{"key":"9068_CR53","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1182\/blood-2024-194650","volume":"144","author":"T Pfeiffer","year":"2024","unstructured":"Pfeiffer T, Hyde S, Shenoy S, Mavers M, Hayashi RJ, Gao F et al (2024) Alemtuzumab, fludarabine, melphalan, and thiotepa as reduced-intensity conditioning regimen for allogeneic hematopoietic cell transplantation in inborn errors of immunity. Blood 144:375. https:\/\/doi.org\/10.1182\/blood-2024-194650","journal-title":"Blood"},{"issue":"3","key":"9068_CR54","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","volume":"104","author":"MB Jordan","year":"2004","unstructured":"Jordan MB, Hildeman D, Kappler J, Marrack P (2004) An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder. Blood 104(3):735\u2013743. https:\/\/doi.org\/10.1182\/blood-2003-10-3413","journal-title":"Blood"},{"issue":"1","key":"9068_CR55","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1146\/annurev-pathol-020117-043625","volume":"13","author":"H Al-Samkari","year":"2018","unstructured":"Al-Samkari H, Berliner N (2018) Hemophagocytic lymphohistiocytosis. Annu Rev Pathol 13(1):27\u201349","journal-title":"Annu Rev Pathol"},{"issue":"6","key":"9068_CR56","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jpeds.2011.11.046","volume":"160","author":"XJ Xu","year":"2012","unstructured":"Xu XJ, Tang YM, Song H, Yang SL, Xu WQ, Zhao N et al (2012) Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatr 160(6):984-990.e981. https:\/\/doi.org\/10.1016\/j.jpeds.2011.11.046","journal-title":"J Pediatr"},{"key":"9068_CR57","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.cyto.2016.05.022","volume":"85","author":"SL Yang","year":"2016","unstructured":"Yang SL, Xu XJ, Tang YM, Song H, Xu WQ, Zhao FY et al (2016) Associations between inflammatory cytokines and organ damage in pediatric patients with hemophagocytic lymphohistiocytosis. Cytokine 85:14\u201317. https:\/\/doi.org\/10.1016\/j.cyto.2016.05.022","journal-title":"Cytokine"},{"key":"9068_CR58","doi-asserted-by":"publisher","first-page":"106356","DOI":"10.1016\/j.intimp.2020.106356","volume":"82","author":"X Yu","year":"2020","unstructured":"Yu X, Song Z, Rao L, Tu Q, Zhou J, Yin Y et al (2020) Synergistic induction of CCL5, CXCL9 and CXCL10 by IFN-\u03b3 and NLRs ligands on human fibroblast-like synoviocytes-a potential immunopathological mechanism for joint inflammation in rheumatoid arthritis. Int Immunopharmacol 82:106356. https:\/\/doi.org\/10.1016\/j.intimp.2020.106356","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"9068_CR59","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Aric\u00f3 M, Egeler RM, Filipovich AH, Imashuku S et al (2007) HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 48(2):124\u2013131","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"9068_CR60","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1182\/blood-2010-01-256099","volume":"116","author":"RA Marsh","year":"2010","unstructured":"Marsh RA, Madden L, Kitchen BJ, Mody R, McClimon B, Jordan MB et al (2010) XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood 116(7):1079\u20131082. https:\/\/doi.org\/10.1182\/blood-2010-01-256099","journal-title":"Blood"},{"issue":"11","key":"9068_CR61","doi-asserted-by":"publisher","first-page":"2918","DOI":"10.1182\/blood.V78.11.2918.2918","volume":"78","author":"JI Henter","year":"1991","unstructured":"Henter JI, Elinder G, S\u00f6der O, Hansson M, Andersson B, Andersson U (1991) Hypercytokinemia in familial hemophagocytic lymphohistiocytosis. Blood 78(11):2918\u20132922","journal-title":"Blood"},{"issue":"11","key":"9068_CR62","doi-asserted-by":"publisher","first-page":"4100","DOI":"10.1182\/blood.V89.11.4100","volume":"89","author":"Y Osugi","year":"1997","unstructured":"Osugi Y, Hara J, Tagawa S, Takai K, Hosoi G, Matsuda Y et al (1997) Cytokine production regulating Th1 and Th2 cytokines in hemophagocytic lymphohistiocytosis. Blood 89(11):4100\u20134103","journal-title":"Blood"},{"issue":"5","key":"9068_CR63","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/icb.2012.9","volume":"90","author":"NA de Weerd","year":"2012","unstructured":"de Weerd NA, Nguyen T (2012) The interferons and their receptors\u2013distribution and regulation. Immunol Cell Biol 90(5):483\u2013491. https:\/\/doi.org\/10.1038\/icb.2012.9","journal-title":"Immunol Cell Biol"},{"issue":"19","key":"9068_CR64","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/1078-0432.Ccr-11-0482","volume":"17","author":"MR Zaidi","year":"2011","unstructured":"Zaidi MR, Merlino G (2011) The two faces of interferon-\u03b3 in cancer. Clin Cancer Res 17(19):6118\u20136124. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-11-0482","journal-title":"Clin Cancer Res"},{"issue":"4","key":"9068_CR65","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.immuni.2009.09.002","volume":"31","author":"X Hu","year":"2009","unstructured":"Hu X, Ivashkiv LB (2009) Cross-regulation of signaling pathways by interferon-gamma: implications for immune responses and autoimmune diseases. Immunity 31(4):539\u2013550. https:\/\/doi.org\/10.1016\/j.immuni.2009.09.002","journal-title":"Immunity"},{"issue":"2","key":"9068_CR66","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1002\/emmm.200900009","volume":"1","author":"J Pachlopnik Schmid","year":"2009","unstructured":"Pachlopnik Schmid J, Ho CH, Chr\u00e9tien F, Lefebvre JM, Pivert G, Kosco-Vilbois M et al (2009) Neutralization of IFNgamma defeats haemophagocytosis in LCMV-infected perforin- and Rab27a-deficient mice. EMBO Mol Med 1(2):112\u2013124. https:\/\/doi.org\/10.1002\/emmm.200900009","journal-title":"EMBO Mol Med"},{"issue":"19","key":"9068_CR67","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C, Cesaro S, Rizzari C, Rao A et al (2020) Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med 382(19):1811\u20131822. https:\/\/doi.org\/10.1056\/NEJMoa1911326","journal-title":"N Engl J Med"},{"issue":"6","key":"9068_CR68","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","volume":"82","author":"F De Benedetti","year":"2023","unstructured":"De Benedetti F, Grom AA, Brogan PA, Bracaglia C, Pardeo M, Marucci G et al (2023) Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis 82(6):857\u2013865. https:\/\/doi.org\/10.1136\/ard-2022-223739","journal-title":"Ann Rheum Dis"},{"key":"9068_CR69","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025977","author":"B Verkamp","year":"2024","unstructured":"Verkamp B, Jodele S, Sabulski A, Marsh RA, Kieser P, Jordan MB (2024) Emapalumab therapy for hemophagocytic lymphohistiocytosis prior to reduced-intensity transplantation improves chimerism. Blood. https:\/\/doi.org\/10.1182\/blood.2024025977","journal-title":"Blood"},{"key":"9068_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/art.42985","author":"S Chandrakasan","year":"2024","unstructured":"Chandrakasan S, Allen CE, Bhatla D, Carter J, Chien M, Cooper R et al (2024) Emapalumab treatment in patients with rheumatologic disease-associated hemophagocytic lymphohistiocytosis in the United States: a retrospective medical chart review study. Arthritis Rheumatol. https:\/\/doi.org\/10.1002\/art.42985","journal-title":"Arthritis Rheumatol"},{"issue":"4","key":"9068_CR71","doi-asserted-by":"publisher","first-page":"663","DOI":"10.21037\/tp-24-72","volume":"13","author":"W Jia","year":"2024","unstructured":"Jia W, Chen X, Luo J, Sumbly V, Kanegane H, He Y (2024) Case report: emapalumab treatment for a pediatric Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) patient with cytokine storm enabling allogeneic hematopoietic cell transplantation. Transl Pediatr 13(4):663\u2013672. https:\/\/doi.org\/10.21037\/tp-24-72","journal-title":"Transl Pediatr"},{"key":"9068_CR72","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1182\/blood-2023-186948","volume":"142","author":"CE Allen","year":"2023","unstructured":"Allen CE, Chandrakasan S, Jordan MB, Leiding JW, Oladapo A, Pednekar P et al (2023) Real-world treatment patterns and outcomes among patients with secondary hemophagocytic lymphohistiocytosis treated with emapalumab in the United States: the real-HLH study. Blood 142:3909","journal-title":"Blood"},{"key":"9068_CR73","doi-asserted-by":"crossref","unstructured":"Xu X-J, Tang Y-M, Song H, Yang S-L, Xu W-Q, Zhao N, et al (2012) Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatrics 160(6):984\u2013990. e981","DOI":"10.1016\/j.jpeds.2011.11.046"},{"issue":"45","key":"9068_CR74","doi-asserted-by":"publisher","first-page":"26943","DOI":"10.1074\/jbc.M115.682138","volume":"290","author":"M Lacroix","year":"2015","unstructured":"Lacroix M, Rousseau F, Guilhot F, Malinge P, Magistrelli G, Herren S et al (2015) Novel insights into interleukin 6 (IL-6) cis- and trans-signaling pathways by differentially manipulating the assembly of the IL-6 signaling complex. J Biol Chem 290(45):26943\u201326953. https:\/\/doi.org\/10.1074\/jbc.M115.682138","journal-title":"J Biol Chem"},{"issue":"3","key":"9068_CR75","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano T (2021) IL-6 in inflammation, autoimmunity and cancer. Int Immunol 33(3):127\u2013148. https:\/\/doi.org\/10.1093\/intimm\/dxaa078","journal-title":"Int Immunol"},{"issue":"6","key":"9068_CR76","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/nrd.2018.45","volume":"17","author":"C Garbers","year":"2018","unstructured":"Garbers C, Heink S, Korn T, Rose-John S (2018) Interleukin-6: designing specific therapeutics for a complex cytokine. Nat Rev Drug Discov 17(6):395\u2013412. https:\/\/doi.org\/10.1038\/nrd.2018.45","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"9068_CR77","doi-asserted-by":"publisher","first-page":"104","DOI":"10.55302\/JMS2361104d","volume":"6","author":"I Dimitrov","year":"2023","unstructured":"Dimitrov I, Sazdov D (2023) Comparison Of Epidemiological And Clinical Parameters In Patients With Severe COVID 19 treated with and without tocilizumab. J Morphological Sci 6(1):104\u2013115","journal-title":"J Morphological Sci"},{"issue":"8","key":"9068_CR78","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1080\/1744666x.2019.1629904","volume":"15","author":"C Kotch","year":"2019","unstructured":"Kotch C, Barrett D, Teachey DT (2019) Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome. Expert Rev Clin Immunol 15(8):813\u2013822. https:\/\/doi.org\/10.1080\/1744666x.2019.1629904","journal-title":"Expert Rev Clin Immunol"},{"issue":"12","key":"9068_CR79","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1080\/13543784.2020.1840549","volume":"29","author":"Z Zhou","year":"2020","unstructured":"Zhou Z, Price CC (2020) Overview on the use of IL-6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. Expert Opin Investig Drugs 29(12):1407\u20131412. https:\/\/doi.org\/10.1080\/13543784.2020.1840549","journal-title":"Expert Opin Investig Drugs"},{"issue":"8","key":"9068_CR80","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA et al (2018) FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist 23(8):943\u2013947. https:\/\/doi.org\/10.1634\/theoncologist.2018-0028","journal-title":"Oncologist"},{"issue":"4","key":"9068_CR81","doi-asserted-by":"publisher","first-page":"254","DOI":"10.2146\/news100012","volume":"67","author":"CA Thompson","year":"2010","unstructured":"Thompson CA (2010) FDA approves tocilizumab to treat rheumatoid arthritis. Am J Health Syst Pharm 67(4):254. https:\/\/doi.org\/10.2146\/news100012","journal-title":"Am J Health Syst Pharm"},{"issue":"1","key":"9068_CR82","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13054-020-02878-7","volume":"24","author":"E Dufranc","year":"2020","unstructured":"Dufranc E, Del Bello A, Belliere J, Kamar N, Faguer S (2020) IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome. Crit Care 24(1):166. https:\/\/doi.org\/10.1186\/s13054-020-02878-7","journal-title":"Crit Care"},{"issue":"1","key":"9068_CR83","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.bjane.2020.10.009","volume":"71","author":"A Eroglu","year":"2021","unstructured":"Eroglu A, Kartal S, Saral OB (2021) Helmet mask and tocilizumab for a patient with hemophagocytic lymphohistiocytosis syndrome and COVID-19: a case report. Braz J Anesthesiol 71(1):79\u201383. https:\/\/doi.org\/10.1016\/j.bjane.2020.10.009","journal-title":"Braz J Anesthesiol"},{"issue":"7","key":"9068_CR84","doi-asserted-by":"publisher","first-page":"e27759","DOI":"10.1002\/pbc.27759","volume":"66","author":"A Wei","year":"2019","unstructured":"Wei A, Ma H, Li Z, Zhang L, Zhang R, Wang T (2019) Successful treatment of a child with idiopathic multicentric Castleman disease associated with hemophagocytic lymphohistiocytosis using tocilizumab. Pediatr Blood Cancer 66(7):e27759. https:\/\/doi.org\/10.1002\/pbc.27759","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"9068_CR85","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1007\/s00277-023-05598-4","volume":"103","author":"K Lv","year":"2024","unstructured":"Lv K, Kong F, Yu M, Zhou Y, Li F (2024) Refractory hemophagocytic lymphohistiocytosis secondary to polatuzumab vedotin plus rituximab and bendamustine. Ann Hematol 103(3):1017\u20131019. https:\/\/doi.org\/10.1007\/s00277-023-05598-4","journal-title":"Ann Hematol"},{"issue":"4","key":"9068_CR86","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.immuni.2019.03.026","volume":"50","author":"S Kang","year":"2019","unstructured":"Kang S, Tanaka T, Narazaki M, Kishimoto T (2019) Targeting interleukin-6 signaling in clinic. Immunity 50(4):1007\u20131023. https:\/\/doi.org\/10.1016\/j.immuni.2019.03.026","journal-title":"Immunity"},{"issue":"14","key":"9068_CR87","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1182\/blood-2010-07-273417","volume":"117","author":"CA Dinarello","year":"2011","unstructured":"Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14):3720\u20133732. https:\/\/doi.org\/10.1182\/blood-2010-07-273417","journal-title":"Blood"},{"issue":"1","key":"9068_CR88","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1111\/imr.12621","volume":"281","author":"CA Dinarello","year":"2018","unstructured":"Dinarello CA (2018) Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev 281(1):8\u201327. https:\/\/doi.org\/10.1111\/imr.12621","journal-title":"Immunol Rev"},{"issue":"2","key":"9068_CR89","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/art.41103","volume":"72","author":"EM Eloseily","year":"2020","unstructured":"Eloseily EM, Weiser P, Crayne CB, Haines H, Mannion ML, Stoll ML et al (2020) Benefit of anakinra in treating pediatric secondary hemophagocytic lymphohistiocytosis. Arthritis Rheumatol 72(2):326\u2013334. https:\/\/doi.org\/10.1002\/art.41103","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"9068_CR90","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s12969-021-00585-3","volume":"19","author":"O Phadke","year":"2021","unstructured":"Phadke O, Rouster-Stevens K, Giannopoulos H, Chandrakasan S, Prahalad S (2021) Intravenous administration of anakinra in children with macrophage activation syndrome. Pediatr Rheumatol Online J 19(1):98. https:\/\/doi.org\/10.1186\/s12969-021-00585-3","journal-title":"Pediatr Rheumatol Online J"},{"issue":"11","key":"9068_CR91","doi-asserted-by":"publisher","first-page":"e28581","DOI":"10.1002\/pbc.28581","volume":"67","author":"S Bami","year":"2020","unstructured":"Bami S, Vagrecha A, Soberman D, Badawi M, Cannone D, Lipton JM et al (2020) The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 67(11):e28581. https:\/\/doi.org\/10.1002\/pbc.28581","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"9068_CR92","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1007\/s12185-022-03430-9","volume":"116","author":"L Naymagon","year":"2022","unstructured":"Naymagon L (2022) Anakinra for the treatment of adult secondary HLH: a retrospective experience. Int J Hematol 116(6):947\u2013955. https:\/\/doi.org\/10.1007\/s12185-022-03430-9","journal-title":"Int J Hematol"},{"issue":"7","key":"9068_CR93","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","volume":"100","author":"JI Henter","year":"2002","unstructured":"Henter JI, Samuelsson-Horne A, Aric\u00f2 M, Egeler RM, Elinder G, Filipovich AH et al (2002) Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood 100(7):2367\u20132373. https:\/\/doi.org\/10.1182\/blood-2002-01-0172","journal-title":"Blood"},{"key":"9068_CR94","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.3389\/fimmu.2019.03089","volume":"10","author":"J Vandenhaute","year":"2019","unstructured":"Vandenhaute J, Wouters CH, Matthys P (2019) Natural killer cells in systemic autoinflammatory diseases: a focus on systemic juvenile idiopathic arthritis and macrophage activation syndrome. Front Immunol 10:3089. https:\/\/doi.org\/10.3389\/fimmu.2019.03089","journal-title":"Front Immunol"},{"issue":"1","key":"9068_CR95","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1182\/blood.V72.1.344.344","volume":"72","author":"A Kist","year":"1988","unstructured":"Kist A, Ho AD, R\u00e4th U, Wiedenmann B, Bauer A, Schlick E et al (1988) Decrease of natural killer cell activity and monokine production in peripheral blood of patients treated with recombinant tumor necrosis factor. Blood 72(1):344\u2013348","journal-title":"Blood"},{"issue":"12","key":"9068_CR96","doi-asserted-by":"publisher","first-page":"2741","DOI":"10.1016\/j.cgh.2021.10.021","volume":"20","author":"EMJ Beelen","year":"2022","unstructured":"Beelen EMJ, Nieboer D, Arkenbosch JHC, Regueiro MD, Satsangi J, Ardizzone S et al (2022) Risk prediction and comparative efficacy of anti-TNF vs thiopurines, for preventing postoperative recurrence in Crohn\u2019s disease: a pooled analysis of 6 trials. Clin Gastroenterol Hepatol 20(12):2741-2752.e2746. https:\/\/doi.org\/10.1016\/j.cgh.2021.10.021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"9068_CR97","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1136\/gutjnl-2019-320022","volume":"70","author":"GR D'Haens","year":"2021","unstructured":"D\u2019Haens GR, van Deventer S (2021) 25 years of anti-TNF treatment for inflammatory bowel disease: lessons from the past and a look to the future. Gut 70(7):1396\u20131405. https:\/\/doi.org\/10.1136\/gutjnl-2019-320022","journal-title":"Gut"},{"issue":"4","key":"9068_CR98","doi-asserted-by":"publisher","first-page":"431","DOI":"10.2174\/0115748863274863231222023853","volume":"19","author":"R Lakhmiri","year":"2024","unstructured":"Lakhmiri R, Cherrah Y, Serragui S (2024) Tumor necrosis alpha (TNF-\u03b1) antagonists used in chronic inflammatory rheumatic diseases: risks and their minimization measures. Curr Drug Saf 19(4):431\u2013443. https:\/\/doi.org\/10.2174\/0115748863274863231222023853","journal-title":"Curr Drug Saf"},{"issue":"1","key":"9068_CR99","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1007\/s10165-007-0006-z","volume":"18","author":"N Takahashi","year":"2008","unstructured":"Takahashi N, Naniwa T, Banno S (2008) Successful use of etanercept in the treatment of acute lupus hemophagocytic syndrome. Mod Rheumatol 18(1):72\u201375. https:\/\/doi.org\/10.1007\/s10165-007-0006-z","journal-title":"Mod Rheumatol"},{"issue":"1","key":"9068_CR100","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/ajh.20462","volume":"81","author":"T Henzan","year":"2006","unstructured":"Henzan T, Nagafuji K, Tsukamoto H, Miyamoto T, Gondo H, Imashuku S et al (2006) Success with infliximab in treating refractory hemophagocytic lymphohistiocytosis. Am J Hematol 81(1):59\u201361. https:\/\/doi.org\/10.1002\/ajh.20462","journal-title":"Am J Hematol"},{"issue":"10","key":"9068_CR101","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1093\/rheumatology\/kem205","volume":"46","author":"H Ideguchi","year":"2007","unstructured":"Ideguchi H, Ohno S, Takase K, Hattori H, Kirino Y, Takeno M et al (2007) Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab. Rheumatology (Oxford) 46(10):1621\u20131622. https:\/\/doi.org\/10.1093\/rheumatology\/kem205","journal-title":"Rheumatology (Oxford)"},{"issue":"22","key":"9068_CR102","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1182\/blood.V114.22.1351.1351","volume":"114","author":"H Ohyagi","year":"2009","unstructured":"Ohyagi H, Onai N, Guo Y-M, Takahashi N, Hirokawa M, Sawada K-I et al (2009) Prevention of hemophagocytosis by TNF-\u03b1 and IL-6 blockade in TLR9- and Nod1- ligand induced hemophagocytic syndrome. Blood 114(22):1351. https:\/\/doi.org\/10.1182\/blood.V114.22.1351.1351","journal-title":"Blood"},{"issue":"4","key":"9068_CR103","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1016\/j.bbmt.2015.12.018","volume":"22","author":"J Liu","year":"2016","unstructured":"Liu J, Guo YM, Onai N, Ohyagi H, Hirokawa M, Takahashi N et al (2016) Cytosine-phosphorothionate-guanine oligodeoxynucleotides exacerbates hemophagocytosis by inducing tumor necrosis factor-alpha production in mice after bone marrow Transplantation. Biol Blood Marrow Transplant 22(4):627\u2013636. https:\/\/doi.org\/10.1016\/j.bbmt.2015.12.018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"9068_CR104","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","volume":"184","author":"R Karki","year":"2021","unstructured":"Karki R, Sharma BR, Tuladhar S, Williams EP, Zalduondo L, Samir P et al (2021) Synergism of TNF-\u03b1 and IFN-\u03b3 triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes. Cell 184(1):149-168.e117. https:\/\/doi.org\/10.1016\/j.cell.2020.11.025","journal-title":"Cell"},{"issue":"29\u201330","key":"9068_CR105","doi-asserted-by":"publisher","first-page":"414","DOI":"10.4414\/smw.2002.10031","volume":"132","author":"D Aeberli","year":"2002","unstructured":"Aeberli D, Oertle S, Mauron H, Reichenbach S, Jordi B, Villiger PM (2002) Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. Swiss Med Wkly 132(29\u201330):414\u2013422. https:\/\/doi.org\/10.4414\/smw.2002.10031","journal-title":"Swiss Med Wkly"},{"issue":"2","key":"9068_CR106","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1002\/pbc.21019","volume":"50","author":"B Makay","year":"2008","unstructured":"Makay B, Yilmaz S, T\u00fcrkyilmaz Z, Unal N, Oren H, Unsal E (2008) Etanercept for therapy-resistant macrophage activation syndrome. Pediatr Blood Cancer 50(2):419\u2013421. https:\/\/doi.org\/10.1002\/pbc.21019","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"9068_CR107","first-page":"2120","volume":"28","author":"S Prahalad","year":"2001","unstructured":"Prahalad S, Bove KE, Dickens D, Lovell DJ, Grom AA (2001) Etanercept in the treatment of macrophage activation syndrome. J Rheumatol 28(9):2120\u20132124","journal-title":"J Rheumatol"},{"issue":"2","key":"9068_CR108","first-page":"401","volume":"30","author":"AV Ramanan","year":"2003","unstructured":"Ramanan AV, Schneider R (2003) Macrophage activation syndrome following initiation of etanercept in a child with systemic onset juvenile rheumatoid arthritis. J Rheumatol 30(2):401\u2013403","journal-title":"J Rheumatol"},{"issue":"1","key":"9068_CR109","first-page":"241","volume":"34","author":"C Sandhu","year":"2007","unstructured":"Sandhu C, Chesney A, Piliotis E, Buckstein R, Koren S (2007) Macrophage activation syndrome after etanercept treatment. J Rheumatol 34(1):241\u2013242","journal-title":"J Rheumatol"},{"issue":"6","key":"9068_CR110","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1093\/rheumatology\/keg187","volume":"42","author":"A Aouba","year":"2003","unstructured":"Aouba A, De Bandt M, Aslangul E, Atkhen N, Patri B (2003) Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. Rheumatology (Oxford) 42(6):800\u2013802. https:\/\/doi.org\/10.1093\/rheumatology\/keg187","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"9068_CR111","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/imr.12616","volume":"281","author":"G Kaplanski","year":"2018","unstructured":"Kaplanski G (2018) Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev 281(1):138\u2013153. https:\/\/doi.org\/10.1111\/imr.12616","journal-title":"Immunol Rev"},{"issue":"11","key":"9068_CR112","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/eji.1830271107","volume":"27","author":"CA Hunter","year":"1997","unstructured":"Hunter CA, Timans J, Pisacane P, Menon S, Cai G, Walker W et al (1997) Comparison of the effects of interleukin-1 alpha, interleukin-1 beta and interferon-gamma-inducing factor on the production of interferon-gamma by natural killer. Eur J Immunol 27(11):2787\u20132792. https:\/\/doi.org\/10.1002\/eji.1830271107","journal-title":"Eur J Immunol"},{"issue":"1","key":"9068_CR113","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/imr.12287","volume":"265","author":"I Jorgensen","year":"2015","unstructured":"Jorgensen I, Miao EA (2015) Pyroptotic cell death defends against intracellular pathogens. Immunol Rev 265(1):130\u2013142. https:\/\/doi.org\/10.1111\/imr.12287","journal-title":"Immunol Rev"},{"key":"9068_CR114","doi-asserted-by":"publisher","first-page":"109388","DOI":"10.1016\/j.cellsig.2019.109388","volume":"63","author":"H M\u00fchl","year":"2019","unstructured":"M\u00fchl H, Bachmann M (2019) IL-18\/IL-18BP and IL-22\/IL-22BP: two interrelated couples with therapeutic potential. Cell Signal 63:109388. https:\/\/doi.org\/10.1016\/j.cellsig.2019.109388","journal-title":"Cell Signal"},{"issue":"1 Pt 1","key":"9068_CR115","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/s0091-6749(99)70518-x","volume":"103","author":"CA Dinarello","year":"1999","unstructured":"Dinarello CA (1999) IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 103(1 Pt 1):11\u201324. https:\/\/doi.org\/10.1016\/s0091-6749(99)70518-x","journal-title":"J Allergy Clin Immunol"},{"issue":"7817","key":"9068_CR116","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41586-020-2422-6","volume":"583","author":"T Zhou","year":"2020","unstructured":"Zhou T, Damsky W, Weizman OE, McGeary MK, Hartmann KP, Rosen CE et al (2020) IL-18BP is a secreted immune checkpoint and barrier to IL-18 immunotherapy. Nature 583(7817):609\u2013614. https:\/\/doi.org\/10.1038\/s41586-020-2422-6","journal-title":"Nature"},{"issue":"5","key":"9068_CR117","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","volume":"139","author":"SW Canna","year":"2017","unstructured":"Canna SW, Girard C, Malle L, de Jesus A, Romberg N, Kelsen J et al (2017) Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition. J Allergy Clin Immunol 139(5):1698\u20131701. https:\/\/doi.org\/10.1016\/j.jaci.2016.10.022","journal-title":"J Allergy Clin Immunol"},{"issue":"6","key":"9068_CR118","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2017-212608","volume":"77","author":"C Gabay","year":"2018","unstructured":"Gabay C, Fautrel B, Rech J, Spertini F, Feist E, K\u00f6tter I et al (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still\u2019s disease. Ann Rheum Dis 77(6):840\u2013847. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212608","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"9068_CR119","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","volume":"59","author":"S Yasin","year":"2020","unstructured":"Yasin S, Fall N, Brown RA, Henderlight M, Canna SW, Girard-Guyonvarc\u2019h C et al (2020) IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome. Rheumatology (Oxford) 59(2):361\u2013366. https:\/\/doi.org\/10.1093\/rheumatology\/kez282","journal-title":"Rheumatology (Oxford)"},{"key":"9068_CR120","doi-asserted-by":"publisher","unstructured":"Novick D (2024) IL-18 and IL-18BP: a unique dyad in health and disease. Int J Mol Sci 25(24). https:\/\/doi.org\/10.3390\/ijms252413505.","DOI":"10.3390\/ijms252413505"},{"issue":"4","key":"9068_CR121","doi-asserted-by":"publisher","first-page":"e129","DOI":"10.1093\/rheumatology\/kead612","volume":"63","author":"\u015e \u00c7a\u011flayan","year":"2024","unstructured":"\u00c7a\u011flayan \u015e, Ulu K, S\u00f6zeri B (2024) Experience of anti-IL-1\u03b2 and anti-IL-18 combined therapy (MAS825) in recurrent and recalcitrant macrophage activation syndrome. Rheumatology (Oxford) 63(4):e129\u2013e131. https:\/\/doi.org\/10.1093\/rheumatology\/kead612","journal-title":"Rheumatology (Oxford)"},{"key":"9068_CR122","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.3389\/fimmu.2018.02642","volume":"9","author":"JE Rood","year":"2018","unstructured":"Rood JE, Burn TN, Neal V, Chu N, Behrens EM (2018) Disruption of IL-33 signaling limits early CD8+ T cell effector function leading to exhaustion in murine hemophagocytic lymphohistiocytosis. Front Immunol 9:2642. https:\/\/doi.org\/10.3389\/fimmu.2018.02642","journal-title":"Front Immunol"},{"issue":"4","key":"9068_CR123","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1182\/blood-2015-07-659813","volume":"127","author":"JE Rood","year":"2016","unstructured":"Rood JE, Rao S, Paessler M, Kreiger PA, Chu N, Stelekati E et al (2016) ST2 contributes to T-cell hyperactivation and fatal hemophagocytic lymphohistiocytosis in mice. Blood 127(4):426\u2013435. https:\/\/doi.org\/10.1182\/blood-2015-07-659813","journal-title":"Blood"},{"key":"9068_CR124","doi-asserted-by":"publisher","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","volume":"12","author":"C Keenan","year":"2021","unstructured":"Keenan C, Nichols KE, Albeituni S (2021) Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis. Front Immunol 12:614704. https:\/\/doi.org\/10.3389\/fimmu.2021.614704","journal-title":"Front Immunol"},{"issue":"5","key":"9068_CR125","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s00281-017-0636-y","volume":"39","author":"XJ Guo","year":"2017","unstructured":"Guo XJ, Thomas PG (2017) New fronts emerge in the influenza cytokine storm. Semin Immunopathol 39(5):541\u2013550. https:\/\/doi.org\/10.1007\/s00281-017-0636-y","journal-title":"Semin Immunopathol"},{"key":"9068_CR126","doi-asserted-by":"publisher","first-page":"2689360","DOI":"10.1155\/2023\/2689360","volume":"2023","author":"Y Dong","year":"2023","unstructured":"Dong Y, Gao R, He K, Zhong J, Dong L (2023) The role of the IL-33\/ST2 axis in CpG-induced macrophage activation syndrome. J Immunol Res 2023:2689360. https:\/\/doi.org\/10.1155\/2023\/2689360","journal-title":"J Immunol Res"},{"issue":"1","key":"9068_CR127","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.semarthrit.2020.12.007","volume":"51","author":"S Tang","year":"2021","unstructured":"Tang S, Li S, Zheng S, Ding Y, Zhu D, Sun C et al (2021) Understanding of cytokines and targeted therapy in macrophage activation syndrome. Semin Arthritis Rheum 51(1):198\u2013210. https:\/\/doi.org\/10.1016\/j.semarthrit.2020.12.007","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"9068_CR128","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.cyto.2013.03.007","volume":"62","author":"S Ishikawa","year":"2013","unstructured":"Ishikawa S, Shimizu M, Ueno K, Sugimoto N, Yachie A (2013) Soluble ST2 as a marker of disease activity in systemic juvenile idiopathic arthritis. Cytokine 62(2):272\u2013277. https:\/\/doi.org\/10.1016\/j.cyto.2013.03.007","journal-title":"Cytokine"},{"issue":"9","key":"9068_CR129","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1177\/0885066617711386","volume":"34","author":"P Wohlfarth","year":"2019","unstructured":"Wohlfarth P, Agis H, Gualdoni GA, Weber J, Staudinger T, Schellongowski P et al (2019) Interleukin 1 receptor antagonist anakinra, intravenous immunoglobulin, and corticosteroids in the management of critically ill adult patients with hemophagocytic lymphohistiocytosis. J Intensive Care Med 34(9):723\u2013731. https:\/\/doi.org\/10.1177\/0885066617711386","journal-title":"J Intensive Care Med"},{"issue":"3","key":"9068_CR130","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/ar3843","volume":"14","author":"SF Bode","year":"2012","unstructured":"Bode SF, Lehmberg K, Maul-Pavicic A, Vraetz T, Janka G, Stadt UZ et al (2012) Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis. Arthritis Res Ther 14(3):213. https:\/\/doi.org\/10.1186\/ar3843","journal-title":"Arthritis Res Ther"},{"key":"9068_CR131","doi-asserted-by":"publisher","first-page":"239","DOI":"10.3389\/fimmu.2012.00239","volume":"3","author":"L Chiossone","year":"2012","unstructured":"Chiossone L, Audonnet S, Chetaille B, Chasson L, Farnarier C, Berda-Haddad Y et al (2012) Protection from inflammatory organ damage in a murine model of hemophagocytic lymphohistiocytosis using treatment with IL-18 binding protein. Front Immunol 3:239. https:\/\/doi.org\/10.3389\/fimmu.2012.00239","journal-title":"Front Immunol"},{"key":"9068_CR132","doi-asserted-by":"publisher","unstructured":"Rood J, Chu N, Kreiger P, Rao S, Stelekati E, Wherry EJ, et al (2015) Interleukin-33 is a mediator of murine familial hemophagocytic lymphohistiocytosis (IRC5P.629). J Immunol 194:58.12\u201358.12. https:\/\/doi.org\/10.4049\/jimmunol.194.Supp.58.12.","DOI":"10.4049\/jimmunol.194.Supp.58.12"},{"issue":"5","key":"9068_CR133","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","volume":"77","author":"S Banerjee","year":"2017","unstructured":"Banerjee S, Biehl A, Gadina M, Hasni S, Schwartz DM (2017) JAK-STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects. Drugs 77(5):521\u2013546. https:\/\/doi.org\/10.1007\/s40265-017-0701-9","journal-title":"Drugs"},{"issue":"1","key":"9068_CR134","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood.V95.1.19","volume":"95","author":"AC Ward","year":"2000","unstructured":"Ward AC, Touw I, Yoshimura A (2000) The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95(1):19\u201329","journal-title":"Blood"},{"issue":"1","key":"9068_CR135","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","volume":"8","author":"C Xue","year":"2023","unstructured":"Xue C, Yao Q, Gu X, Shi Q, Yuan X, Chu Q et al (2023) Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer. Signal Transduct Target Ther 8(1):204. https:\/\/doi.org\/10.1038\/s41392-023-01468-7","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"9068_CR136","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/0092-8674(93)90415-m","volume":"74","author":"LS Argetsinger","year":"1993","unstructured":"Argetsinger LS, Campbell GS, Yang X, Witthuhn BA, Silvennoinen O, Ihle JN et al (1993) Identification of JAK2 as a growth hormone receptor-associated tyrosine kinase. Cell 74(2):237\u2013244. https:\/\/doi.org\/10.1016\/0092-8674(93)90415-m","journal-title":"Cell"},{"key":"9068_CR137","doi-asserted-by":"publisher","unstructured":"Harrison DA (2012) The Jak\/STAT pathway. Cold Spring Harb Perspect Biol 4(3). https:\/\/doi.org\/10.1101\/cshperspect.a011205.","DOI":"10.1101\/cshperspect.a011205"},{"issue":"15","key":"9068_CR138","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2020008738","volume":"137","author":"A Kalinichenko","year":"2021","unstructured":"Kalinichenko A, Perinetti Casoni G, Dupr\u00e9 L, Trotta L, Huemer J, Galgano D et al (2021) RhoG deficiency abrogates cytotoxicity of human lymphocytes and causes hemophagocytic lymphohistiocytosis. Blood 137(15):2033\u20132045. https:\/\/doi.org\/10.1182\/blood.2020008738","journal-title":"Blood"},{"key":"9068_CR139","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1756-8722-6-90","volume":"6","author":"M Furqan","year":"2013","unstructured":"Furqan M, Akinleye A, Mukhi N, Mittal V, Chen Y, Liu D (2013) STAT inhibitors for cancer therapy. J Hematol Oncol 6:90. https:\/\/doi.org\/10.1186\/1756-8722-6-90","journal-title":"J Hematol Oncol"},{"key":"9068_CR140","doi-asserted-by":"publisher","first-page":"106210","DOI":"10.1016\/j.intimp.2020.106210","volume":"80","author":"P Xin","year":"2020","unstructured":"Xin P, Xu X, Deng C, Liu S, Wang Y, Zhou X et al (2020) The role of JAK\/STAT signaling pathway and its inhibitors in diseases. Int Immunopharmacol 80:106210. https:\/\/doi.org\/10.1016\/j.intimp.2020.106210","journal-title":"Int Immunopharmacol"},{"issue":"13","key":"9068_CR141","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1182\/blood-2015-12-684399","volume":"127","author":"R Das","year":"2016","unstructured":"Das R, Guan P, Sprague L, Verbist K, Tedrick P, An QA et al (2016) Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis. Blood 127(13):1666\u20131675. https:\/\/doi.org\/10.1182\/blood-2015-12-684399","journal-title":"Blood"},{"key":"9068_CR142","doi-asserted-by":"publisher","first-page":"1137037","DOI":"10.3389\/fimmu.2023.1137037","volume":"14","author":"S Albeituni","year":"2023","unstructured":"Albeituni S, Oak N, Tillman HS, Stroh A, Keenan C, Bloom M et al (2023) Cellular and transcriptional impacts of Janus kinase and\/or IFN-gamma inhibition in a mouse model of primary hemophagocytic lymphohistiocytosis. Front Immunol 14:1137037. https:\/\/doi.org\/10.3389\/fimmu.2023.1137037","journal-title":"Front Immunol"},{"issue":"1","key":"9068_CR143","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1182\/blood-2016-02-700013","volume":"128","author":"S Maschalidi","year":"2016","unstructured":"Maschalidi S, Sepulveda FE, Garrigue A, Fischer A, de Saint BG (2016) Therapeutic effect of JAK1\/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice. Blood 128(1):60\u201371. https:\/\/doi.org\/10.1182\/blood-2016-02-700013","journal-title":"Blood"},{"issue":"12","key":"9068_CR144","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1016\/s2352-3026(19)30156-5","volume":"6","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Merrill SA, Alsawah F, Bockenstedt P, Campagnaro E, Devata S et al (2019) Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol 6(12):e630\u2013e637. https:\/\/doi.org\/10.1016\/s2352-3026(19)30156-5","journal-title":"Lancet Haematol"},{"issue":"11","key":"9068_CR145","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1007\/s00432-020-03301-y","volume":"146","author":"L Zhou","year":"2020","unstructured":"Zhou L, Liu Y, Wen Z, Yang S, Li M, Zhu Q et al (2020) Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome. J Cancer Res Clin Oncol 146(11):3063\u20133074. https:\/\/doi.org\/10.1007\/s00432-020-03301-y","journal-title":"J Cancer Res Clin Oncol"},{"issue":"17","key":"9068_CR146","doi-asserted-by":"publisher","first-page":"4577","DOI":"10.1182\/blood-2011-06-356261","volume":"118","author":"H Trottestam","year":"2011","unstructured":"Trottestam H, Horne A, Aric\u00f2 M, Egeler RM, Filipovich AH, Gadner H et al (2011) Chemoimmunotherapy for hemophagocytic lymphohistiocytosis: long-term results of the HLH-94 treatment protocol. Blood 118(17):4577\u20134584. https:\/\/doi.org\/10.1182\/blood-2011-06-356261","journal-title":"Blood"},{"issue":"19","key":"9068_CR147","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1182\/bloodadvances.2017007526","volume":"1","author":"L Broglie","year":"2017","unstructured":"Broglie L, Pommert L, Rao S, Thakar M, Phelan R, Margolis D et al (2017) Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. Blood Adv 1(19):1533\u20131536. https:\/\/doi.org\/10.1182\/bloodadvances.2017007526","journal-title":"Blood Adv"},{"issue":"4","key":"9068_CR148","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1111\/bjh.17331","volume":"193","author":"J Wang","year":"2021","unstructured":"Wang J, Zhang R, Wu X, Li F, Yang H, Liu L et al (2021) Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory\/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial. Br J Haematol 193(4):761\u2013768. https:\/\/doi.org\/10.1111\/bjh.17331","journal-title":"Br J Haematol"},{"issue":"1","key":"9068_CR149","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.jaci.2022.07.026","volume":"151","author":"JA Joly","year":"2023","unstructured":"Joly JA, Vall\u00e9e A, Bourdin B, Bourbonnais S, Patey N, Gaboury L et al (2023) Combined IFN-\u03b3 and JAK inhibition to treat hemophagocytic lymphohistiocytosis in mice. J Allergy Clin Immunol 151(1):247-259.e247. https:\/\/doi.org\/10.1016\/j.jaci.2022.07.026","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"9068_CR150","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/s41423-019-0270-9","volume":"17","author":"S Xia","year":"2020","unstructured":"Xia S, Liu X, Cao X, Xu S (2020) T-cell expression of Bruton\u2019s tyrosine kinase promotes autoreactive T-cell activation and exacerbates aplastic anemia. Cell Mol Immunol 17(10):1042\u20131052. https:\/\/doi.org\/10.1038\/s41423-019-0270-9","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"9068_CR151","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/ppo.0000000000000412","volume":"25","author":"JA Burger","year":"2019","unstructured":"Burger JA (2019) Bruton tyrosine kinase inhibitors: present and future. Cancer J 25(6):386\u2013393. https:\/\/doi.org\/10.1097\/ppo.0000000000000412","journal-title":"Cancer J"},{"issue":"14","key":"9068_CR152","doi-asserted-by":"publisher","first-page":"3514","DOI":"10.1158\/1078-0432.Ccr-20-1427","volume":"26","author":"EA Chong","year":"2020","unstructured":"Chong EA, Roeker LE, Shadman M, Davids MS, Schuster SJ, Mato AR (2020) BTK inhibitors in cancer patients with COVID-19: \u201cThe winner will be the one who controls that chaos\u201d (Napoleon Bonaparte). Clin Cancer Res 26(14):3514\u20133516. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-20-1427","journal-title":"Clin Cancer Res"},{"issue":"Pt A","key":"9068_CR153","doi-asserted-by":"publisher","first-page":"113040","DOI":"10.1016\/j.intimp.2024.113040","volume":"142","author":"Q Ding","year":"2024","unstructured":"Ding Q, Zhou Y, Feng Y, Sun L, Zhang T (2024) Bruton\u2019s tyrosine kinase: a promising target for treating systemic lupus erythematosus. Int Immunopharmacol 142(Pt A):113040. https:\/\/doi.org\/10.1016\/j.intimp.2024.113040","journal-title":"Int Immunopharmacol"},{"key":"9068_CR154","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.3389\/fimmu.2020.02001","volume":"11","author":"YH Yeh","year":"2020","unstructured":"Yeh YH, Hsieh MY, Lee WI, Huang JL, Chen LC, Yeh KW et al (2020) Distinct clinical features and novel mutations in Taiwanese patients with X-linked agammaglobulinemia. Front Immunol 11:2001. https:\/\/doi.org\/10.3389\/fimmu.2020.02001","journal-title":"Front Immunol"},{"key":"9068_CR155","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3389\/fimmu.2019.01953","volume":"10","author":"SP Han","year":"2019","unstructured":"Han SP, Lin YF, Weng HY, Tsai SF, Fu LS (2019) A novel BTK gene mutation in a child with atypical X-linked agammaglobulinemia and recurrent hemophagocytosis: a case report. Front Immunol 10:1953. https:\/\/doi.org\/10.3389\/fimmu.2019.01953","journal-title":"Front Immunol"},{"key":"9068_CR156","doi-asserted-by":"publisher","first-page":"108816","DOI":"10.1016\/j.clim.2021.108816","volume":"230","author":"M Stack","year":"2021","unstructured":"Stack M, Sacco K, Castagnoli R, Livinski AA, Notarangelo LD, Lionakis MS (2021) BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a systematic review. Clin Immunol 230:108816. https:\/\/doi.org\/10.1016\/j.clim.2021.108816","journal-title":"Clin Immunol"},{"issue":"1","key":"9068_CR157","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/leu.2016.262","volume":"31","author":"M Ruella","year":"2017","unstructured":"Ruella M, Kenderian SS, Shestova O, Klichinsky M, Melenhorst JJ, Wasik MA et al (2017) Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms. Leukemia 31(1):246\u2013248. https:\/\/doi.org\/10.1038\/leu.2016.262","journal-title":"Leukemia"},{"key":"9068_CR158","doi-asserted-by":"publisher","first-page":"115664","DOI":"10.1016\/j.ejmech.2023.115664","volume":"259","author":"J Huang","year":"2023","unstructured":"Huang J, Ma Z, Yang Z, He Z, Bao J, Peng X et al (2023) Discovery of Ibrutinib-based BTK PROTACs with in vivo anti-inflammatory efficacy by inhibiting NF-\u03baB activation. Eur J Med Chem 259:115664. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115664","journal-title":"Eur J Med Chem"},{"key":"9068_CR159","doi-asserted-by":"publisher","first-page":"5381","DOI":"10.1182\/blood-2024-210260","volume":"144","author":"J Wang","year":"2024","unstructured":"Wang J, Song D, Wu L, Wei N, Pi Y, Wang Z (2024) Zanubrutinib as salvage therapy for refractory\/relapsed hemophagocytic lymphohistiocytosis in adults: a single center, prospective study. Blood 144:5381. https:\/\/doi.org\/10.1182\/blood-2024-210260","journal-title":"Blood"},{"issue":"4","key":"9068_CR160","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cell.2006.02.015","volume":"124","author":"S Akira","year":"2006","unstructured":"Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124(4):783\u2013801. https:\/\/doi.org\/10.1016\/j.cell.2006.02.015","journal-title":"Cell"},{"issue":"5","key":"9068_CR161","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/ni.1863","volume":"11","author":"T Kawai","year":"2010","unstructured":"Kawai T, Akira S (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11(5):373\u2013384. https:\/\/doi.org\/10.1038\/ni.1863","journal-title":"Nat Immunol"},{"issue":"34","key":"9068_CR162","first-page":"2389","volume":"90","author":"ZS Wang","year":"2010","unstructured":"Wang ZS, Xu DM, Guan GJ, Cui MY, Wei Y, Tang LJ et al (2010) Clinical significance of toll-like receptor 4 expression on the surface of peripheral blood mononuclear cells in uremic patients. Zhonghua Yi Xue Za Zhi 90(34):2389\u20132391","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"6","key":"9068_CR163","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1172\/jci43157","volume":"121","author":"EM Behrens","year":"2011","unstructured":"Behrens EM, Canna SW, Slade K, Rao S, Kreiger PA, Paessler M et al (2011) Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice. J Clin Invest 121(6):2264\u20132277. https:\/\/doi.org\/10.1172\/jci43157","journal-title":"J Clin Invest"},{"issue":"4","key":"9068_CR164","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1084\/jem.20062447","volume":"204","author":"K Crozat","year":"2007","unstructured":"Crozat K, Hoebe K, Ugolini S, Hong NA, Janssen E, Rutschmann S et al (2007) Jinx, an MCMV susceptibility phenotype caused by disruption of Unc13d: a mouse model of type 3 familial hemophagocytic lymphohistiocytosis. J Exp Med 204(4):853\u2013863. https:\/\/doi.org\/10.1084\/jem.20062447","journal-title":"J Exp Med"},{"issue":"5","key":"9068_CR165","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1002\/art.33496","volume":"64","author":"R Strippoli","year":"2012","unstructured":"Strippoli R, Carvello F, Scianaro R, De Pasquale L, Vivarelli M, Petrini S et al (2012) Amplification of the response to Toll-like receptor ligands by prolonged exposure to interleukin-6 in mice: implication for the pathogenesis of macrophage activation syndrome. Arthritis Rheum 64(5):1680\u20131688. https:\/\/doi.org\/10.1002\/art.33496","journal-title":"Arthritis Rheum"},{"key":"9068_CR166","doi-asserted-by":"crossref","unstructured":"Tian T, Wang J, Gao X, Yin G, Xu J, Qiu H, et al. Expression and clinical significance of Toll-like receptor 4 on peripheral blood CD14 + monocytes of patients with secondary haemophagocytic lymphohistiocytosis2023.","DOI":"10.21203\/rs.3.rs-3210542\/v1"},{"issue":"24","key":"9068_CR167","doi-asserted-by":"publisher","first-page":"6582","DOI":"10.1182\/blood-2011-01-329607","volume":"117","author":"P Krebs","year":"2011","unstructured":"Krebs P, Crozat K, Popkin D, Oldstone MB, Beutler B (2011) Disruption of MyD88 signaling suppresses hemophagocytic lymphohistiocytosis in mice. Blood 117(24):6582\u20136588. https:\/\/doi.org\/10.1182\/blood-2011-01-329607","journal-title":"Blood"},{"key":"9068_CR168","doi-asserted-by":"publisher","first-page":"892864","DOI":"10.3389\/fcimb.2022.892864","volume":"12","author":"H Cui","year":"2022","unstructured":"Cui H, Zhang C, Zhang C, Cai Z, Chen L, Chen Z et al (2022) Anti-influenza effect and mechanisms of lentinan in an ICR mouse model. Front Cell Infect Microbiol 12:892864. https:\/\/doi.org\/10.3389\/fcimb.2022.892864","journal-title":"Front Cell Infect Microbiol"},{"key":"9068_CR169","doi-asserted-by":"crossref","unstructured":"Kumar A, Bharadwaj T, Muthuraj L, Kumar J, R P, Lalitha R, et al. Molecular dynamics simulation and docking studies reveals inhibition of NF-kB signaling as a promising therapeutic drug target for reduction in cytokines Storms2024.","DOI":"10.21203\/rs.3.rs-4914623\/v1"},{"key":"9068_CR170","doi-asserted-by":"publisher","first-page":"111095","DOI":"10.1016\/j.mce.2020.111095","volume":"520","author":"FV Francisqueti-Ferron","year":"2021","unstructured":"Francisqueti-Ferron FV, Garcia JL, Ferron AJT, Nakandakare-Maia ET, Gregolin CS, Silva J et al (2021) Gamma-oryzanol as a potential modulator of oxidative stress and inflammation via PPAR-y in adipose tissue: a hypothetical therapeutic for cytokine storm in COVID-19? Mol Cell Endocrinol 520:111095. https:\/\/doi.org\/10.1016\/j.mce.2020.111095","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"9068_CR171","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1089\/vim.2010.0016","volume":"23","author":"J Bassaganya-Riera","year":"2010","unstructured":"Bassaganya-Riera J, Song R, Roberts PC, Hontecillas R (2010) PPAR-gamma activation as an anti-inflammatory therapy for respiratory virus infections. Viral Immunol 23(4):343\u2013352. https:\/\/doi.org\/10.1089\/vim.2010.0016","journal-title":"Viral Immunol"},{"key":"9068_CR172","doi-asserted-by":"publisher","unstructured":"Gopal R, Mendy A, Marinelli MA, Richwalls LJ, Seger PJ, Patel S, et al (2019) Peroxisome proliferator-activated receptor gamma (PPAR) suppresses inflammation and bacterial clearance during influenza-bacterial super-infection. Viruses 11(6). https:\/\/doi.org\/10.3390\/v11060505.","DOI":"10.3390\/v11060505"},{"issue":"1","key":"9068_CR173","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3851\/imp1490","volume":"15","author":"WC Hsieh","year":"2010","unstructured":"Hsieh WC, Lan BS, Chen YL, Chang Y, Chuang HC, Su IJ (2010) Efficacy of peroxisome proliferator activated receptor agonist in the treatment of virus-associated haemophagocytic syndrome in a rabbit model. Antivir Ther 15(1):71\u201381. https:\/\/doi.org\/10.3851\/imp1490","journal-title":"Antivir Ther"},{"key":"9068_CR174","doi-asserted-by":"publisher","first-page":"968336","DOI":"10.3389\/fimmu.2022.968336","volume":"13","author":"A Gopalakrishnan","year":"2022","unstructured":"Gopalakrishnan A, Joseph J, Shirey KA, Keegan AD, Boukhvalova MS, Vogel SN et al (2022) Protection against influenza-induced acute lung injury (ALI) by enhanced induction of M2a macrophages: possible role of PPAR\u03b3\/RXR ligands in IL-4-induced M2a macrophage differentiation. Front Immunol 13:968336. https:\/\/doi.org\/10.3389\/fimmu.2022.968336","journal-title":"Front Immunol"},{"issue":"3","key":"9068_CR175","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/nri.2017.108","volume":"18","author":"AH Sharpe","year":"2018","unstructured":"Sharpe AH, Pauken KE (2018) The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 18(3):153\u2013167. https:\/\/doi.org\/10.1038\/nri.2017.108","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"9068_CR176","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1182\/blood-2007-11-123141","volume":"111","author":"T Azuma","year":"2008","unstructured":"Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L (2008) B7\u2013H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 111(7):3635\u20133643. https:\/\/doi.org\/10.1182\/blood-2007-11-123141","journal-title":"Blood"},{"issue":"10","key":"9068_CR177","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1084\/jem.20100637","volume":"207","author":"J Fourcade","year":"2010","unstructured":"Fourcade J, Sun Z, Benallaoua M, Guillaume P, Luescher IF, Sander C et al (2010) Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J Exp Med 207(10):2175\u20132186. https:\/\/doi.org\/10.1084\/jem.20100637","journal-title":"J Exp Med"},{"issue":"4","key":"9068_CR178","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1097\/ppo.0000000000000060","volume":"20","author":"S Yao","year":"2014","unstructured":"Yao S, Chen L (2014) PD-1 as an immune modulatory receptor. Cancer J 20(4):262\u2013264. https:\/\/doi.org\/10.1097\/ppo.0000000000000060","journal-title":"Cancer J"},{"key":"9068_CR179","doi-asserted-by":"publisher","first-page":"1127599","DOI":"10.3389\/fimmu.2023.1127599","volume":"14","author":"Y Zhao","year":"2023","unstructured":"Zhao Y, Deng Y, Jiang Y, Zheng W, Tan Y, Yang Z et al (2023) Case report: Targeting the PD-1 receptor and genetic mutations validated in primary histiocytic sarcoma with hemophagocytic lymphohistiocytosis. Front Immunol 14:1127599. https:\/\/doi.org\/10.3389\/fimmu.2023.1127599","journal-title":"Front Immunol"},{"key":"9068_CR180","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clim.2019.03.006","volume":"202","author":"Z Gao","year":"2019","unstructured":"Gao Z, Wang Y, Wang J, Zhang J, Wang Z (2019) The inhibitory receptors on NK cells and CTLs are upregulated in adult and adolescent patients with secondary hemophagocytic lymphohistiocytosis. Clin Immunol 202:18\u201328. https:\/\/doi.org\/10.1016\/j.clim.2019.03.006","journal-title":"Clin Immunol"},{"issue":"7077","key":"9068_CR181","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH et al (2006) Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439(7077):682\u2013687. https:\/\/doi.org\/10.1038\/nature04444","journal-title":"Nature"},{"issue":"11","key":"9068_CR182","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1182\/blood.2019003886","volume":"135","author":"P Liu","year":"2020","unstructured":"Liu P, Pan X, Chen C, Niu T, Shuai X, Wang J et al (2020) Nivolumab treatment of relapsed\/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults. Blood 135(11):826\u2013833. https:\/\/doi.org\/10.1182\/blood.2019003886","journal-title":"Blood"},{"key":"9068_CR183","doi-asserted-by":"publisher","first-page":"3751","DOI":"10.2147\/idr.S372998","volume":"15","author":"Y Pi","year":"2022","unstructured":"Pi Y, Wang J, Wang Z (2022) Successful treatment of relapsed Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis after Allo-HSCT with PD-1 blockade: a case report. Infect Drug Resist 15:3751\u20133756. https:\/\/doi.org\/10.2147\/idr.S372998","journal-title":"Infect Drug Resist"},{"issue":"5","key":"9068_CR184","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1007\/s00432-022-04147-2","volume":"149","author":"Y He","year":"2023","unstructured":"He Y, Gao Y, Ping L, He H, Huang C, Bai B et al (2023) The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK\/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. J Cancer Res Clin Oncol 149(5):2017\u20132027. https:\/\/doi.org\/10.1007\/s00432-022-04147-2","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"9068_CR185","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1007\/s00277-023-05476-z","volume":"102","author":"Y Xu","year":"2023","unstructured":"Xu Y, Li W, Gan J, He X, Huang X (2023) An analysis of sintilimab combined with ruxolitinib as compassionate therapy for 12 adults with EBV-associated hemophagocytic lymphohistiocytosis. Ann Hematol 102(12):3325\u20133333. https:\/\/doi.org\/10.1007\/s00277-023-05476-z","journal-title":"Ann Hematol"},{"key":"9068_CR186","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejca.2019.07.014","volume":"122","author":"JM Michot","year":"2019","unstructured":"Michot JM, Lazarovici J, Tieu A, Champiat S, Voisin AL, Ebbo M et al (2019) Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage? Eur J Cancer 122:72\u201390. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.014","journal-title":"Eur J Cancer"},{"issue":"1","key":"9068_CR187","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/annonc\/mdw537","volume":"28","author":"M Takeshita","year":"2017","unstructured":"Takeshita M, Anai S, Mishima S, Inoue K (2017) Coincidence of immunotherapy-associated hemophagocytic syndrome and rapid tumor regression. Ann Oncol 28(1):186\u2013189. https:\/\/doi.org\/10.1093\/annonc\/mdw537","journal-title":"Ann Oncol"},{"key":"9068_CR188","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.ejca.2017.02.016","volume":"77","author":"N Malissen","year":"2017","unstructured":"Malissen N, Lacotte J, Du-Thanh A, Gaudy-Marqueste C, Guillot B, Grob JJ (2017) Macrophage activation syndrome: a new complication of checkpoint inhibitors. Eur J Cancer 77:88\u201389. https:\/\/doi.org\/10.1016\/j.ejca.2017.02.016","journal-title":"Eur J Cancer"},{"key":"9068_CR189","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.ejca.2018.01.063","volume":"93","author":"I Satzger","year":"2018","unstructured":"Satzger I, Ivanyi P, L\u00e4nger F, Kreipe HH, Schaper-Gerhardt K, Beutel G et al (2018) Treatment-related hemophagocytic lymphohistiocytosis secondary to checkpoint inhibition with nivolumab plus ipilimumab. Eur J Cancer 93:150\u2013153. https:\/\/doi.org\/10.1016\/j.ejca.2018.01.063","journal-title":"Eur J Cancer"},{"issue":"7","key":"9068_CR190","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1093\/annonc\/mdy175","volume":"29","author":"K Sasaki","year":"2018","unstructured":"Sasaki K, Uehara J, Iinuma S, Doi H, Honma M, Toki Y et al (2018) Hemophagocytic lymphohistiocytosis associated with dabrafenib and trametinib combination therapy following pembrolizumab administration for advanced melanoma. Ann Oncol 29(7):1602\u20131603. https:\/\/doi.org\/10.1093\/annonc\/mdy175","journal-title":"Ann Oncol"},{"issue":"12","key":"9068_CR191","doi-asserted-by":"publisher","first-page":"7781","DOI":"10.4049\/jimmunol.175.12.7781","volume":"175","author":"EM van Beek","year":"2005","unstructured":"van Beek EM, Cochrane F, Barclay AN, van den Berg TK (2005) Signal regulatory proteins in the immune system. J Immunol 175(12):7781\u20137787. https:\/\/doi.org\/10.4049\/jimmunol.175.12.7781","journal-title":"J Immunol"},{"issue":"4","key":"9068_CR192","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.immuni.2015.08.021","volume":"43","author":"T Yi","year":"2015","unstructured":"Yi T, Li J, Chen H, Wu J, An J, Xu Y et al (2015) Splenic dendritic cells survey red blood cells for missing self-CD47 to trigger adaptive immune responses. Immunity 43(4):764\u2013775. https:\/\/doi.org\/10.1016\/j.immuni.2015.08.021","journal-title":"Immunity"},{"key":"9068_CR193","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1146\/annurev-immunol-032713-120142","volume":"32","author":"AN Barclay","year":"2014","unstructured":"Barclay AN, Van den Berg TK (2014) The interaction between signal regulatory protein alpha (SIRP\u03b1) and CD47: structure, function, and therapeutic target. Annu Rev Immunol 32:25\u201350. https:\/\/doi.org\/10.1146\/annurev-immunol-032713-120142","journal-title":"Annu Rev Immunol"},{"issue":"10","key":"9068_CR194","doi-asserted-by":"publisher","first-page":"2821","DOI":"10.4049\/jimmunol.2000652","volume":"205","author":"K Kidder","year":"2020","unstructured":"Kidder K, Bian Z, Shi L, Liu Y (2020) Inflammation unrestrained by SIRP\u03b1 induces secondary hemophagocytic lymphohistiocytosis independent of IFN-\u03b3. J Immunol 205(10):2821\u20132833. https:\/\/doi.org\/10.4049\/jimmunol.2000652","journal-title":"J Immunol"},{"issue":"Supplement 1","key":"9068_CR195","doi-asserted-by":"publisher","first-page":"8318","DOI":"10.1182\/blood-2022-168013","volume":"140","author":"E Rose","year":"2022","unstructured":"Rose E, Moore SJ, Cai A, He A, Huck I, Razo J et al (2022) Characterization of ELA026, a clinical-stage monoclonal antibody that rapidly and potently depletes myeloid cells and T lymphocytes. Blood 140(Supplement 1):8318\u20138319","journal-title":"Blood"},{"key":"9068_CR196","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1182\/blood-2023-177795","volume":"142","author":"A Maiti","year":"2023","unstructured":"Maiti A, Daver N, Iyer SP, McCall D, Gohil SH, Jimenez JL et al (2023) A phase 1b study of ELA026, a monoclonal antibody targeting signal regulatory protein-\u03b1\/\u03b21\/\u03b3, in patients with newly diagnosed and previously treated secondary hemophagocytic lymphohistiocytosis. Blood 142:1162","journal-title":"Blood"},{"issue":"2","key":"9068_CR197","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","volume":"24","author":"MP Chao","year":"2012","unstructured":"Chao MP, Weissman IL, Majeti R (2012) The CD47-SIRP\u03b1 pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol 24(2):225\u2013232. https:\/\/doi.org\/10.1016\/j.coi.2012.01.010","journal-title":"Curr Opin Immunol"}],"container-title":["Clinical Reviews in Allergy &amp; Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09068-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12016-025-09068-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12016-025-09068-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T09:02:06Z","timestamp":1749459726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12016-025-09068-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,9]]},"references-count":197,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["9068"],"URL":"https:\/\/doi.org\/10.1007\/s12016-025-09068-9","relation":{},"ISSN":["1559-0267"],"issn-type":[{"value":"1559-0267","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,9]]},"assertion":[{"value":"29 May 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"56"}}